Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306254 | 1.00 | HSD11B1 (0.57) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 | |
| SCHEMBL31046817 | 0.85 | UGT2B7 (0.52) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 | |
| SCHEMBL8983490 | 0.85 | UGT2B7 (0.52) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 | |
| SCHEMBL8099850 | 0.81 | CYP2D6 (0.70) | HSD11B1CYP2D6KDM4EALDH1A1MC4R | |
| SCHEMBL1586528 | 0.81 | CYP2D6 (0.70) | HSD11B1CYP2D6KDM4EALDH1A1MC4R | |
| SCHEMBL19613500 | 0.81 | CYP2D6 (0.70) | HSD11B1CYP2D6KDM4EALDH1A1MC4R | |
| SCHEMBL4601165 | 0.81 | CYP2D6 (0.70) | HSD11B1CYP2D6KDM4EALDH1A1MC4R | |
| SCHEMBL6313012 | 0.78 | MCHR1 (0.53) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 | |
| SCHEMBL6208247 | 0.78 | MCHR1 (0.53) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 | |
| SCHEMBL6187443 | 0.78 | MCHR1 (0.53) | HSD11B1MCHR1UGT2B7CYP2D6DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | HSD11B1 235/4885MCHR1 1/4885UGT2B7 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.